A Phase 1/2a Study of BMS-986179 Administered in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1/2a Study of BMS-986179 Administered in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs BMS 986179 (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Jul 2016 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
    • 05 Jul 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
    • 24 Jun 2016 Planned number of patients changed from 204 to 216.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top